Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer

Clinical Cancer Research

Volumn 17, Issue 19, 2011, Pages 6272-6286

  Nishino, Ryohei ^a,c   Takano, Atsushi ^a,b   Oshita, Hideto ^a   Ishikawa, Nobuhisa ^a   Akiyama, Hirohiko ^d   Ito, Hiroyuki ^e   Nakayama, Haruhiko ^e   Miyagi, Yohei ^e   Tsuchiya, Eiju ^e   Kohno, Nobuoki ^c   Nakamura, Yusuke ^a   Daigo, Yataro ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS INDUCED GENE 3 PROTEIN; SECRETORY PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TISSUE MICROARRAY; VALIDATION STUDY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PROGNOSIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053474761     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0060     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
3. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004;78:216-21. (Pubitemid 38833935)
4. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53:61-6. (Pubitemid 23019377)
5. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 2008;56:43-53. (Pubitemid 351311467)
6. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205. (Pubitemid 36539569)
7. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99. (Pubitemid 36577045)
8. Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43. (Pubitemid 40045258)
9. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006;28:799-805.
10. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29:567-75.
11. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41. (Pubitemid 37413435)
12. Kato T, Daigo Y, Hayama S, Ishikawa N, Yamabuki T, Ito T, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65:5638-46. (Pubitemid 40911164)
13. Furukawa C, Daigo Y, Ishikawa N, Kato T, Ito T, Tsuchiya E, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10. (Pubitemid 41161239)
14. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005;65:11314-25. (Pubitemid 41821688)
15. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Tanaka S, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006;97:737-45. (Pubitemid 43983786)
16. Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, et al. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19. (Pubitemid 44623637)
17. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48. (Pubitemid 44799753)
18. Kato T, Hayama S, Yamabuki Y, Ishikawa N, Miyamoto M, Ito T, et al. Increased expression of IGF-II mRNA-binding protein 1 is associated with the tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42. (Pubitemid 46225347)
19. Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007;6:542-51. (Pubitemid 46332456)
20. Hayama S, Daigo Y, Yamabuki T, Hirata D, Kato T, Miyamoto M, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67:4113-22. (Pubitemid 46815056)
21. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007;13:6624-31. (Pubitemid 350206797)
22. Mano Y, Takahashi K, Ishikawa N, Takano A, Yasui W, Inai K, et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007;98:1902-13. (Pubitemid 350002196)
23. Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, et al. Activation of holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53. (Pubitemid 47437429)
24. Kato T, Sato N, Takano A, Miyamoto M, Nishimura H, Tsuchiya E, et al. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 2008;14:2363-70. (Pubitemid 351551069)
25. Dunleavy EM, Roche D, Tagami H, Lacoste N, Ray-Gallet D, Nakamura Y, et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009;137:485-97.
26. Hirata D, Yamabuki T, Miki D, Ito T, Tsuchiya E, Fujita M, et al. Involvement of epithelial cell transforming sequence 2 (ECT2) oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009;15:256-66.
27. Sato N, Koinuma J, Fujita M, Hosokawa M, Ito T, Tsuchiya E, et al. Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res 2010;16:226-39.
28. Sato N, Koinuma J, Ito T, Tsuchiya E, Kondo S, Nakamura Y, et al. Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes Chromosomes Cancer 2010;49:353-67.
29. Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res 2010;70:5337-47.
30. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70. (Pubitemid 40053398)
31. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84. (Pubitemid 41507981)
32. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67:2517-25. (Pubitemid 46548936)
33. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
34. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703.
35. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010;70:5326-36.
36. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8. (Pubitemid 47489730)
37. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54. (Pubitemid 351761737)
38. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, et al. HLA-A2- restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumorreactive CTL. Int J Cancer 2008;123:2616-25.
39. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
40. Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, et al. The forkhead box M1 transcription factor, as a possible immunotherapeutic tumor-associated antigen. Int J Cancer 2010;126:2153-63.
41. Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells. Cancer Sci 2011;102:697-705.
42. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996;70:1143-53. (Pubitemid 26029036)
43. Skorstengaard K, Jensen MS, Sahl P, Petersen TE, Magnusson S. Complete primary structure of bovine plasma fibronectin. Eur J Biochem 1986;161:441-53. (Pubitemid 17044658)
44. Devergne O, Coulomb-L'Hermine A, Capel F, Moussa M, Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol 2001;159:1763-76. (Pubitemid 33062519)
45. Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, Hermine O, et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 2005;166:1217-28. (Pubitemid 40524444)
46. Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40- related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002;198:310-6. (Pubitemid 35277381)
47. Sobin L, Wittekind Ch. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
48. Chin SF, Daigo Y, Huang HE, Iyer NG, Callagy G, Kranjac T, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56:275-9. (Pubitemid 37243919)
49. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43. (Pubitemid 13033817)
50. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Herminé A, Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008;181:6898-905.